Ebos Group (ASX:EBO) ROCE %: 8.84% (As of Dec. 2025)


ASX:EBO Ebos Group Ltd ASX:EBO
77 GF Score
Price A$16.76
GF Value A$31.49
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Ebos Group ROCE %?

Ebos Group ASX:EBO +0.30% 77 ROCE % is 8.84% as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 77/100 and a GF Value™ of A$31.49 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Ebos Group's annualized ROCE % for the quarter that ended in Dec. 2025 was 8.84%.

Ebos Group  (ASX:EBO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Ebos Group ROCE % Related Terms

Ebos Group ROCE % Historical Data

* Premium members only.

The historical data trend for Ebos Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ebos Group ROCE % Chart

Ebos Group Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.00 10.94 11.67 12.71 9.41

Ebos Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.60 12.04 9.94 8.22 8.84
ASX:EBO
77GF Score
Ebos Group Ltd ASX:EBO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ebos Group ROCE % Calculation

Ebos Group's annualized ROCE % for the fiscal year that ended in Jun. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Jun. 2025 )  (A: Jun. 2024 )(A: Jun. 2025 )
=390.931/( ( (6812.546 - 3156.123) + (7264.738 - 2610.065) )/ 2 )
=390.931/( (3656.423+4654.673)/ 2 )
=390.931/4155.548
=9.41 %

Ebos Group's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=422.986/( ( (7264.738 - 2610.065) + (7655.37 - 2736.581) )/ 2 )
=422.986/( ( 4654.673 + 4918.789 )/ 2 )
=422.986/4786.731
=8.84 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 8.84% mean?
Ebos Group (ASX:EBO) has a ROCE % of 8.84% as of Dec. 2025.
Is Ebos Group's ROCE % too high?
Ebos Group's current ROCE % is 8.84%. The Medical Distribution industry median ROCE % is 9.22. Ebos Group's value of 8.84% is 4.1% below this industry median. Overall, Ebos Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's ROCE % compare to MCK and COR?
Ebos Group's ROCE % of 8.84% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 9.22. Ebos Group's value of 8.84% is 4.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 9.22, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current ROCE % of 8.84% is 4.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 9.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current ROCE % is 8.84%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.49, compared to a current price of A$16.76 — trading 46.8% below its estimated fair value. The current ROCE % is 8.84% and 4.1% below the Medical Distribution industry median of 9.22. Ebos Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current ROCE % is 8.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ebos Group (ASX:EBO) Overvalued in 2026?

Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued. The current stock price of A$16.76 is trading 46.8% below its estimated GF Value™ of A$31.49. GuruFocus considers Ebos Group to be Significantly Undervalued.

Key valuation signals for ASX:EBO:

  • ROCE %: 8.84%
  • GF Value™: A$31.49 vs. price of A$16.76 (46.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs
  • Industry Position: 4.1% below the Medical Distribution median

No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ebos Group Business Description

Address 737 Bourke Street, Level 7, Docklands, Melbourne, VIC, AUS, 3008
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
77GF Score

Get the complete analysis for ASX:EBO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$16.76
Price
A$31.49
GF Value